Key result
A model combining PEAR1, PTGS1, and homocysteine predicts cerebral infarction recurrence with ~0.72 AUC.
Why the study?
To evaluate the predictive potential of PTGS1 and PEAR1 gene polymorphisms, combined with biochemical and demographic factors, for aspirin resistance and cerebral infarction recurrence.
Do PEAR1 and PTGS1 gene polymorphisms combined with homocysteine levels predict the recurrence of cerebral infarction in patients on aspirin therapy?
Cohort (n=280)
No
Do PEAR1 and PTGS1 gene polymorphisms combined with homocysteine levels predict the recurrence of cerebral infarction in patients on aspirin therapy?
The integration of PEAR1 and PTGS1 gene polymorphisms with homocysteine levels provides a moderately accurate model for predicting cerebral infarction recurrence, potentially guiding individualized antiplatelet therapy.
May refine post-infarction risk stratification in cohorts; leaves open whether it guides aspirin therapy.
Introduction This study aimed to evaluate the predictive potential of prostaglandin-endoperoxide synthase 1 ( PTGS1 ) and platelet endothelial aggregation receptor-1 ( PEAR1 ) gene polymorphisms, in combination with biochemical and demographic factors, for aspirin resistance (AR) and recurrence with cerebral infarction (CI) in Chinese patients. Methods A retrospective study was conducted on 280 patients diagnosed with CI and admitted to the Department of Neurology, Affiliated Hospital of Beihua University, between January and December 2021. Based on follow-up via telephone, patients were categorized into recurrent (n = 97) and non-recurrent (n = 183) groups. Clinical data, including age, sex, smoking and alcohol history, presence of coronary heart disease, diabetes, and hypertension, were collected. Laboratory indices measured upon admission included hemoglobin, triglycerides, total cholesterol, uric acid, and homocysteine (HCY) levels. Genotyping for PEAR1 and PTGS1 was performed. Univariate and multivariate logistic regression analyses were conducted to identify independent predictors of recurrence. A combined prediction model was developed, and receiver operating characteristic (ROC) curves were used to evaluate predictive performance. Results Significant differences were observed between the recurrent and non-recurrent groups in the distribution of PEAR1 and PTGS1 genotypes, the presence of hypertension, and levels of HCY ( p < 0.05). Multivariate logistic regression identified PEAR1 and PTGS1 polymorphisms, as well as elevated HCY, as independent predictors of cerebral infarction recurrence ( p < 0.05). ROC analysis demonstrated the following area under the curve (AUC) values for predicting recurrence: PEAR1 = 0.529, PTGS1 = 0.642, HCY = 0.696, and the combined prediction model = 0.721. The combined model showed significantly improved predictive value compared to individual markers ( p < 0.05). Conclusion PEAR1 and PTGS1 gene polymorphisms, when integrated with biochemical markers, such as HCY, could effectively predict the risk of recurrence in patients with cerebral infarction. The combined model has offered superior predictive value, supporting its potential clinical utility in guiding antiplatelet therapy for individualized risk stratification.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2025) conducted a cohort in Cerebral Infarction (n=280). Combined prediction model (PEAR1, PTGS1, and HCY) vs. Individual predictors was evaluated on Prediction of cerebral infarction recurrence (AUC 0.721, 95% CI 0.659-0.783, p=< 0.001). A combined prediction model incorporating PEAR1 and PTGS1 gene polymorphisms with homocysteine levels effectively predicted the risk of cerebral infarction recurrence with an AUC of 0.721.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: